MMP9 and breast carcinoma: These authors showed that PPARγ ligands reduced the invasive capabilities of MDA-MB-231 breast cancer cells, enhancing the ratio of metallopeptidase inhibitor 1 (TIMP-1), the tissue inhibitor of MMPs, to MMP-9 with a consequent reduction of the activity of this enzyme [102].